CoDa raises $20M in first venture round

New Zealand's CoDa Therapeutics has raised $10 million in venture capital, raising its total first round financing to $20 million. Domain Associates and GBS Ventures led the round and much of the money has been earmarked for clinical trials of its tissue repair program.

- read the report on the round from the New Zealand Herald

ALSO: REGiMMUNE has raised $4.2 million in its second round of venture capital financing. The original lead investor NIF SMBC Ventures led the round. Release

PLUS: SV Life Sciences, formerly Schroder Ventures Life Sciences, today announced the final closing of SV Life Sciences Fund IV with total commitments of $572 million. Release

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.